Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
about
A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimenOptimizing drug development in oncology by clinical trial simulation: Why and how?Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.
P2860
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Bevacizumab Pharmacokinetics I ...... ic Colorectal Cancer Patients.
@en
type
label
Bevacizumab Pharmacokinetics I ...... ic Colorectal Cancer Patients.
@en
prefLabel
Bevacizumab Pharmacokinetics I ...... ic Colorectal Cancer Patients.
@en
P2093
P2860
P1476
Bevacizumab Pharmacokinetics I ...... ic Colorectal Cancer Patients.
@en
P2093
Aurélie Ferru
Christophe Borg
David Ternant
Denis Smith
Driffa Moussata
Eric Terrebone
Gilles Paintaud
Julie Léger
Jérôme Rollin
Morgane Caulet
P2860
P2888
P304
P356
10.1007/S40262-016-0406-3
P577
2016-06-16T00:00:00Z
P6179
1003042245